Shire plc - Statement re: Media Speculation
11 Jul, 2014, 19:00 BST
DUBLIN, July 11, 2014 /PRNewswire/ --
Not for release, publication or distribution (in whole or in part) in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.
Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: SHPG) notes the Bloomberg article this afternoon. Shire confirms it has held a meeting with representatives of AbbVie.
This statement is being made by Shire without the prior agreement or approval of AbbVie.
A further update will be made when appropriate. Shareholders are strongly advised to take no action in relation to AbbVie's proposal. There can be no certainty that any firm offer will be made nor as to the terms on which any firm offer might be made.
A copy of this announcement will be available at http://www.shire.com. The content of the website referred to in this announcement is not incorporated into and does not form part of this announcement.
Notes to editors
Shire enables people with life-altering conditions to lead better lives.
Our strategy is to focus on developing and marketing innovative specialty medicines to meet significant unmet patient needs.
We focus on providing treatments in Neuroscience, Rare Diseases, Gastrointestinal, and Internal Medicine and we are developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmology.
CONTACTS
Shire
Stephanie Fagan
+1-201-572-9581
FTI Consulting (Media Adviser to the Company)
Andrew Lorenz (London)
+44-77-7564-1807
Ben Atwell (London)
+44-20-3727-1000
David B. Roady (New York)
+1-212-850-5600
Robert Stanislaro (New York)
+1-212-850-5600
SOURCE Shire plc